Julie Brevard

934 total citations
18 papers, 512 citations indexed

About

Julie Brevard is a scholar working on Genetics, Hematology and Immunology. According to data from OpenAlex, Julie Brevard has authored 18 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Hematology and 4 papers in Immunology. Recurrent topics in Julie Brevard's work include Acute Myeloid Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Hemoglobinopathies and Related Disorders (3 papers). Julie Brevard is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Hemoglobinopathies and Related Disorders (3 papers). Julie Brevard collaborates with scholars based in United States, Australia and United Kingdom. Julie Brevard's co-authors include Sarah Lord, Simon H. Budman, Emil Chiauzzi, Patrick Kelly, Robert D. Arbeit, Nathaniel P. Katz, Timothy J. Sullivan, Errol P. Prens, Egilius L.H. Spierings and Erica S. Klaassen and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and Neuro-Oncology.

In The Last Decade

Julie Brevard

18 papers receiving 496 citations

Peers

Julie Brevard
Comparison fields: 5 of 93
  • Molecular Biology 111
  • Clinical Psychology 96
  • Epidemiology 80
  • Immunology 77
  • Public Health, Environmental and Occupational Health 68
Nicolas Batty United States
Qiao Chu China
Victoria Goldberg Argentina
Rahul Suresh United States
Fangping Chen China
Federica Ricci Italy
Megan N. Perez United States
Babak Nejati Iran
Ville Autio Finland
Fenglan Lou China
Nicolas Batty United States View profile →
Citations per field, relative to Julie Brevard
Julie Brevard · 1×
Citations per year, relative to Julie Brevard
Julie Brevard · 1×

Countries citing papers authored by Julie Brevard

Since Specialization
Citations

This map shows the geographic impact of Julie Brevard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Brevard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Brevard more than expected).

Fields of papers citing papers by Julie Brevard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Brevard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Brevard. The network helps show where Julie Brevard may publish in the future.

Co-authorship network of co-authors of Julie Brevard

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Brevard. A scholar is included among the top collaborators of Julie Brevard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Brevard. Julie Brevard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
# Work Indexed citations
1
S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
2022 ·HemaSphere ·Ashutosh Lal, R. Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Cameron C. Trenor, (unknown), Sujit Sheth
2
2
Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
2022 ·Blood ·Jörge E. Cortes, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Pierre Péterlin, Olga Polyanskaya, Jennifer Sweeney, Julie Brevard, (unknown), Stéphane de Botton
6
3
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
2022 ·Neuro-Oncology ·Macarena I. de la Fuente, Howard Colman, Mark Rosenthal, Brian Andrew Van Tine, (unknown), Tobias Walbert, Hui Gan, María Vieito, Mohammed Milhem, (unknown), (unknown), Sylvie M. Guichard, (unknown), (unknown), Julie Brevard, Patrick Kelly, Hesham Mohamed, Varun Monga
52
4
Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease
2021 ·Blood ·Ashutosh Lal, R. Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, (unknown), Sujit Sheth
2
5
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
2020 ·Diabetes Obesity and Metabolism ·Carine Beysen, Patricia Schroeder, Eric Wu, Julie Brevard, Maria Ribadeneira, Wei Lu, Kiran Dole, Terry O’Reilly, Linda Morrow, Marcus Hompesch, Marc K. Hellerstein, Kelvin W. Li, L. E. B. Johansson, Patrick Kelly
42
6
An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)
2020 ·Blood ·Kenneth W. Wood, James Geib, Eric Wu, (unknown), (unknown), Kenneth I. Ataga, Jo Howard, Jeremie H. Estepp, Marilyn J. Telen, Julie Brevard
4
7
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects
2020 ·ACS Chemical Neuroscience ·Damon Young, Michael Popiolek, Patrick Trapa, Kari R. Fonseca, Julie Brevard, David Gray, Rouba Kozak
18
8
Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies
2019 ·Blood ·Manish R. Patel, Guillermo Garcia‐Manero, Ronald Paquette, Shira Dinner, William B. Donnellan, Michael R. Grunwald, Maria Ribadeneira, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, Jeffrey E. Lancet
22
9
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
2019 ·Blood ·Jörge E. Cortes, Eunice S. Wang, Justin M. Watts, Sangmin Lee, Maria R. Baer, (unknown), Shira Dinner, Jay Yang, William B. Donnellan, Anthony P. Schwarer, Christian Récher, Patrick Kelly, Jennifer Sweeney, Julie Brevard, Patrick Henrick, (unknown), Sylvie M. Guichard, Hesham Mohamed, Andrew H. Wei
16
10
ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY
2019 ·Neuro-Oncology ·Macarena I. de la Fuente, Howard Colman, Mark Rosenthal, Brian Andrew Van Tine, Ekokobe Fonkem, Tobias Walbert, Mohammed Milhem, (unknown), (unknown), Sylvie M. Guichard, Julie Brevard, (unknown), Blythe Thomson, Varun Monga
1
11
PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY
2019 ·HemaSphere ·Stéphane de Botton, Justin M. Watts, Maria R. Baer, (unknown), Shira Dinner, (unknown), Karen Seiter, Thomas Prébet, Gary J. Schiller, P. Brent Ferrell, Kim Dao, Patrick Kelly, (unknown), (unknown), Julie Brevard, Qian Xu, Patrick Henrick, Hesham Mohamed, Jörge E. Cortes
2
12
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis
2016 ·Clinical Immunology ·Deepak M.W. Balak, Martijn B. A. van Doorn, Robert D. Arbeit, (unknown), Erica S. Klaassen, Timothy J. Sullivan, Julie Brevard, Hok Bing Thio, Errol P. Prens, Jacobus Burggraaf, Robert Rißmann
75
13
AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis
2016 ·Annals of the Rheumatic Diseases ·Patrick Gordon, Robert G. Cooper, Hector Chinoy, David Isenberg, Ingrid E. Lundberg, Victoria P. Werth, Kirsten L. Gruis, Mark E. Hurtt, Julie Brevard, Linda Granlund, David Fiorentino
5
14
Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
2015 ·Blood ·Sheeba K. Thomas, Wael A. Harb, J. Thaddeus Beck, (unknown), M. Lia Palomba, Stephen M. Ansell, Herbert Eradat, Edward N. Libby, Ranjana H. Advani, Julio Hajdenberg, Leonard T. Heffner, James E. Hoffman, David H. Vesole, (unknown), (unknown), Julie Brevard, James J. O’Leary, Sudhir Agrawal
10
15
Teaching adolescents about changing bodies: Randomized controlled trial of an Internet puberty education and body dissatisfaction prevention program
2010 ·Body Image ·Tara M. Cousineau, ­Debra L. Franko, (unknown), Diana Rancourt, (unknown), (unknown), Julie Brevard
25
16
Connecting to Young Adults: An Online Social Network Survey of Beliefs and Attitudes Associated With Prescription Opioid Misuse Among College Students
2010 ·Substance Use & Misuse ·Sarah Lord, Julie Brevard, Simon H. Budman
116
17
MyStudentBody–Stress: An Online Stress Management Intervention for College Students
2008 ·Journal of Health Communication ·Emil Chiauzzi, Julie Brevard, (unknown), (unknown), Sarah Lord
94
18
Two-Minute Skin Anesthesia Through Ultrasound Pretreatment and Iontophoretic Delivery of a Topical Anesthetic: A Feasibility Study
2008 ·Pain Medicine ·Egilius L.H. Spierings, Julie Brevard, Nathaniel P. Katz
20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Batty Breakdown of academic impact, for papers by Qiao Chu Breakdown of academic impact, for papers by Victoria Goldberg Breakdown of academic impact, for papers by Rahul Suresh Breakdown of academic impact, for papers by Fangping Chen Breakdown of academic impact, for papers by Federica Ricci Breakdown of academic impact, for papers by Megan N. Perez Breakdown of academic impact, for papers by Babak Nejati Breakdown of academic impact, for papers by Ville Autio Breakdown of academic impact, for papers by Fenglan Lou
Rankless by CCL
2026